In 2022,Long, Keith; Vaughn, Zoe; McDaniels, Michael David; Joyasawal, Sipak; Przepiorski, Aneta; Parasky, Emily; Sander, Veronika; Close, David; Johnston, Paul A.; Davidson, Alan J.; de Caestecker, Mark; Hukriede, Neil A.; Huryn, Donna M. published an article in ACS Pharmacology & Translational Science. The title of the article was 《Validation of HDAC8 Inhibitors as Drug Discovery Starting Points to Treat Acute Kidney Injury》.Name: Methyl 3-bromopropanoate The author mentioned the following in the article:
Acute kidney injury (AKI), a sudden loss of kidney function, is a common and serious condition for which there are no approved specific therapies. While there are multiple approaches to treat the underlying causes of AKI, no targets have been clin. validated. Here, we assessed a series of potent, selective competitive inhibitors of histone deacetylase 8 (HDAC8), a promising therapeutic target in an AKI setting. Using biochem. assays, zebrafish AKI phenotypic assays, and human kidney organoid assays, we show that selective HDAC8 inhibitors can lead to efficacy in increasingly stringent models. One of these, PCI-34051, was efficacious in a rodent model of AKI, further supporting the potential for HDAC8 inhibitors and, in particular, this scaffold as a therapeutic approach to AKI. In the experiment, the researchers used many compounds, for example, Methyl 3-bromopropanoate(cas: 3395-91-3Name: Methyl 3-bromopropanoate)
Methyl 3-bromopropanoate(cas: 3395-91-3) belongs to bromides. A variety of minor organobromine compounds are found in nature, but none are biosynthesized or required by mammals. Organobromine compounds have fallen under increased scrutiny for their environmental impact.Name: Methyl 3-bromopropanoate
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary